Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

NCT04732845 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: Fully human anti CD19 CAR-T Cell Dose
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Benjamin Tomlinson